These findings highlight the protective roles of bile acid receptor agonists in diminishing chronic inflammation and fibrosis—presumably by attenuating inflammasome activity—in hepatobiliary and gastrointestinal disorders such as PSC and IBD. The gene discussed is NR1H4; the disease is inflammatory bowel disease.